Table 1.
Baseline characteristics of patients in this real-world study.
| Items | All (n = 224) | Moderate/Severe (n = 126) | Mild (n = 98) |
p | Missing % | |
|---|---|---|---|---|---|---|
| Demographic features | Gender (%) | 213 (95.1) | 123 (97.6) | 90 (91.8) | 0.062 | 0 |
| Age (y) | 34.09 (10.91) | 33.98 (11.74) | 34.23 (9.80) | 0.422 | 0 | |
| Han | 211 (94.20) | 117 (92.86) | 94 (95.92) | 0.398 | 0 | |
| Uygur | 13 (5.80) | 9 (7.14) | 4 (4.08) | 0.398 | 0 | |
| SLE duration (y) | 7.65 (6.29) | 6.61 (5.41) | 8.98 (7.06) | 0.014 | 0 | |
| SLE duration ≤ 2 y (%) | 65 (29.0) | 43 (34.1) | 22 (22.4) | 0.075 | 0 | |
| Follow up (m) | 11.72 (5.11) | 10.94 (4.69) | 12.73 (5.46) | 0.011 | 0 | |
| Laboratory results | Anti-dsDNA+ (%) | 169 (75.4) | 105 (83.3) | 64 (65.3) | 0.003 | 11.6 |
| Complement 3 (g/L) | 0.63 (0.21) | 0.58 (0.18) | 0.70 (0.22) | <0.001 | 4.9 | |
| Low C3 (%) * | 148 (66.1) | 95 (75.4) | 53 (54.1) | 0.001 | 4.9 | |
| Complement 4 (g/L) | 0.12 (0.09) | 0.11 (0.09) | 0.13 (0.08) | 0.036 | 6.3 | |
| Low C4 (%) * | 101 (45.1) | 63 (50.0) | 38 (38.8) | 0.124 | 6.3 | |
| IgG (g/L) | 13.36 (5.24) | 13.38 (5.58) | 13.33 (4.81) | 0.984 | 17.9 | |
| Organ involvement | Mucocutaneous | 60 (26.8) | 43 (34.1) | 17 (17.3) | 0.006 | 0 |
| Musculoskeletal | 47 (21.0) | 30 (23.8) | 17 (17.3) | 0.252 | 0 | |
| Renal | 75 (33.5) | 61 (48.4) | 14 (14.3) | <0.001 | 0 | |
| Hematologic | 38 (17.0) | 27 (21.4) | 11 (11.2) | 0.049 | 0 | |
| Neurological | 5 (2.2) | 4 (3.2) | 1 (1.0) | 0.389 | 0 | |
| Disease evaluation | SLEDAI | 7.72 (4.46) | 10.68 (3.63) | 3.91 (1.64) | <0.001 | 0 |
| SDI | 0.49 (0.72) | 0.48 (0.70) | 0.50 (0.75) | 0.858 | 0.9 | |
| PGA | 1.34 (0.62) | 1.62 (0.55) | 0.96 (0.51) | <0.001 | 0.4 | |
| Baseline Therapy | Prednisone (mg/d) | 23.97 (19.68) | 31.12 (21.61) | 14.77 (11.70) | <0.001 | 0 |
| HCQ (%) | 198 (88.4) | 113 (89.7) | 85 (86.7) | 0.533 | 0 | |
| IS (%) | 134 (59.8) | 83 (65.9) | 51 (52.0) | 0.040 | 0 | |
| MMF (%) | 69 (30.8) | 41 (32.5) | 28 (28.6) | / | 0 | |
| CTX (%) | 13 (5.8) | 12 (9.5) | 1 (1.0) | / | 0 | |
| CNI (%) | 43 (19.2) | 26 (20.6) | 17 (17.4) | / | 0 | |
| Others (%) | 9 (4.02) | 4 (3.1) | 5 (5.1) | / | 0 |
* C3/C4: complement 3/4.